Bronchogen
Also known as Ala-Glu-Asp-Leu, AEDL
A tetrapeptide bioregulator from the Khavinson family designed to support respiratory tissue and bronchial health through tissue-specific gene regulation.
Regulatory Pathway
Dosing Protocol
Typical Dose
10-20 mg daily
Frequency
Once or twice daily
Duration
10-30 day cycles
Timing & Administration
Administer via Oral capsules or sublingual. Frequency: Once or twice daily.
Popular Uses
Mechanism of Action
Regulates gene expression in bronchial epithelial cells and lung tissue through peptide signaling to normalize cellular function and facilitate tissue repair in the respiratory system.
Research Summary
Evidence level: animal studies. Clinical status: Preclinical research, approved in Russia as supplement.
Side Effects & Safety
Important Warnings
- Limited human safety data beyond Russian research
- Not FDA approved.
References
No references available.
Related Peptides
Browse all →A tetrapeptide bioregulator (Lys-Glu-Asp-Ala) developed by Khavinson that modulates chromatin structure. Studies in elderly subjects (75-88 years) showed activation of ribosomal genes.
View profileA tripeptide bioregulator targeting liver and gastrointestinal tissue, derived from liver tissue extracts. Modulates gene expression related to detoxification, antioxidant defense, and cellular repair.
View profileA tetrapeptide bioregulator (Ala-Glu-Asp-Pro) derived from cerebral cortex extracts. Studied for neuroprotection, neural differentiation, and cognitive support.
View profile